Ultragenyx Pharmaceutical (RARE) Non-Current Assets (2013 - 2026)
Ultragenyx Pharmaceutical (RARE) reported Non-Current Assets of $639.0 million for Q1 2026, up 4.28% year-over-year from $612.8 million in Q1 2025, and up 9.98% on a QoQ basis from $581.0 million in Q4 2025.
Ultragenyx Pharmaceutical (RARE) has 14 years of Non-Current Assets data on file, last reported at $639.0 million in Q1 2026.
- Quarterly Non-Current Assets rose 4.28% year-over-year to $639.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (down 12.54% YoY) and the FY2025 annual result came in at $581.0 million, down 15.31% from the prior year.
- Non-Current Assets grew to $639.0 million in Q1 2026 per RARE's latest filing, from $581.0 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $758.8 million in Q4 2023 and bottomed at $547.2 million in Q3 2025.
- The 5-year median for Non-Current Assets is $639.0 million (2026), against an average of $645.1 million.
- The widest annual swing landed in 2022, when Non-Current Assets grew 28.41%; it then decreased 25.92% in 2025.
- Tracing RARE's Non-Current Assets over 5 years: stood at $661.5 million in 2022, then rose by 14.71% to $758.8 million in 2023, then declined by 9.6% to $686.0 million in 2024, then fell by 15.31% to $581.0 million in 2025, then advanced by 9.98% to $639.0 million in 2026.
- Per Business Quant, the three latest RARE Non-Current Assets figures stand at $639.0 million (Q1 2026), $581.0 million (Q4 2025), and $547.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | 639.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 639.00 Mn |
| Dec 31, 2025 | 581.00 Mn |
| Sep 30, 2025 | 547.24 Mn |
| Jun 30, 2025 | 586.48 Mn |
| Mar 31, 2025 | 612.77 Mn |
| Dec 31, 2024 | 686.00 Mn |
| Sep 30, 2024 | 738.76 Mn |
| Jun 30, 2024 | 653.80 Mn |
| Mar 31, 2024 | 711.11 Mn |
| Dec 31, 2023 | 758.83 Mn |
| Sep 30, 2023 | 638.95 Mn |
| Jun 30, 2023 | 609.17 Mn |
| Mar 31, 2023 | 617.07 Mn |
| Dec 31, 2022 | 661.55 Mn |
| Sep 30, 2022 | 605.81 Mn |
| Jun 30, 2022 | 642.09 Mn |
| Mar 31, 2022 | 676.51 Mn |
| Dec 31, 2021 | 665.79 Mn |
| Sep 30, 2021 | 637.92 Mn |
| Jun 30, 2021 | 562.95 Mn |
| Mar 31, 2021 | 526.83 Mn |
| Dec 31, 2020 | 464.25 Mn |
| Sep 30, 2020 | 396.38 Mn |
| Mar 31, 2020 | 338.82 Mn |
| Dec 31, 2019 | 284.48 Mn |
| Sep 30, 2019 | 266.46 Mn |
| Jun 30, 2019 | 259.50 Mn |
| Mar 31, 2019 | 220.87 Mn |
| Dec 31, 2018 | 197.19 Mn |
| Sep 30, 2018 | 197.67 Mn |
| Jun 30, 2018 | 201.28 Mn |
| Mar 31, 2018 | 235.77 Mn |
| Dec 31, 2017 | 221.17 Mn |
| Sep 30, 2017 | 44.14 Mn |
| Jun 30, 2017 | 77.75 Mn |
| Mar 31, 2017 | 101.14 Mn |
| Dec 31, 2016 | 138.93 Mn |
| Sep 30, 2016 | 98.38 Mn |
| Jun 30, 2016 | 70.87 Mn |
| Mar 31, 2016 | 93.95 Mn |
| Dec 31, 2015 | 109.36 Mn |
| Sep 30, 2015 | 141.42 Mn |
| Jun 30, 2015 | 6.47 Mn |
| Mar 31, 2015 | 5.33 Mn |
| Dec 31, 2014 | 4.55 Mn |
| Sep 30, 2014 | 4.19 Mn |
| Jun 30, 2014 | 4.37 Mn |
| Mar 31, 2014 | 3.07 Mn |
| Dec 31, 2013 | 4.42 Mn |